Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.
Moser R, Annis J, Nikolova O, Whatcott C, Gurley K, Mendez E, Moran-Jones K, Dorrell C, Sears RC, Kuo C, Han H, Biankin A, Grandori C, Von Hoff DD, Kemp CJ.
Moser R, et al. Among authors: von hoff dd.
Cancer Res. 2022 Sep 16;82(18):3375-3393. doi: 10.1158/0008-5472.CAN-21-4222.
Cancer Res. 2022.
PMID: 35819261
Free PMC article.